Ed Zhang, MBA

Ed serves as Co-founder and CEO at Overland Pharmaceuticals, a leading cross-border biotech platform company in Asia and US focused on advance technology modality in oncology and autoimmune diseases. Ed co-founded Overland as a venture partner at Hillhouse Capital in 2020. Under his leadership, Overland has established an initial portfolio of 10 pipeline programs with two platform technologies through strategic partnerships with Allogene and ADC Therapeutics. Since its inception, Overland has expanded its team to more than 90 employees worldwide in the past two years and started building out a world-class cell therapy GMP manufacturing facility in Asia.

Before starting at Hillhouse, Ed was VP Corporate Development at Boston Pharmaceuticals which represents a differentiated business model focused on translational clinical development. As part of its initial founding team, Ed led corporate development and strategic initiatives including establishing partnership with leading global pharma and biotech companies. Prior to joining Boston Pharma, Ed headed global business development at Sanofi’s Specialty Products BU and was Director of Strategic Development at Genzyme before its acquisition by Sanofi. Ed has a total of over 18-year biopharma industrial experience and started his career as a medicinal chemist at Pharmacia & Upjohn.

Ed holds B.S. from Nanjing University and M.B.A. from Kellogg School of Management at Northwestern University.